Jefferies Financial Group’s Sarepta Therapeutics SRPT Stock Holding History

Jefferies Financial Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-45,000	Closed	-$770K	–	1670
2025 Q2	$770K	Buy	+45,000	New	+$1.92M	0.01%	801
2024 Q1	–	Sell	-3,700	Closed	-$357K	–	2009
2023 Q4	$357K	Sell	3,700 -13,500	-78%	-$1.3M	﹤0.01%	1326
2023 Q3	$2.08M	Hold	17,200	–	–	0.02%	616
2023 Q2	$1.97M	Sell	17,200 -19,500	-53%	-$2.51M	0.02%	661
2023 Q1	$5.06M	Sell	36,700 -100,800	-73%	-$13.1M	0.04%	356
2022 Q4	$17.8M	Buy	+137,500	New	+$15.9M	0.12%	131

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Jefferies Financial Group's SRPT Position: Q2 2026 in Review

Jefferies Financial Group increased its Sarepta Therapeutics (SRPT) stake by 141% in Q2 2026, buying an estimated $2.1M and bringing the position to 190,200 shares worth $3.42M. The position accounts for 0.02% of the portfolio, ranked #505.

Jefferies Financial Group first reported a position in SRPT in Q4 2022 and has held it in 8 quarters since. The position peaked at $8.98M in Q4 2022. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Jefferies Financial Group held 190,200 shares of Sarepta Therapeutics worth $3.42M as of Q2 2026.
Jefferies Financial Group bought 111,220 Sarepta Therapeutics shares in Q2 2026, an estimated $2.1M.
Sarepta Therapeutics made up 0.02% of Jefferies Financial Group's portfolio in Q2 2026, its #505 holding.
Jefferies Financial Group first reported a position in Sarepta Therapeutics in Q4 2022 and has held it in 8 quarters since.
Jefferies Financial Group's Sarepta Therapeutics position peaked at $8.98M in Q4 2022.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.